For example, metastatic ER+ tumours have a higher rate of ESR1 mutations (range 12–56%) compared to primary breast cancers (0.4%, The Cancer Genome Atlas (TCGA), https://www.cancer.gov/tcga (accessed on30 December 2020)). This evidence concerns the gene ESR1 and neoplasm.